Advertisement

Topics

NSAV Announces Launch of Heartrescue.net

20:00 EDT 31 Jul 2017 | Marketwired

CRESCO, PA -- (Marketwired) -- 08/01/17 -- NSAV Holding, Inc. (OTC: NSAV) announced today the launch of an upgraded version of China's premier cardiac emergency response website, http://www.heartrescue.net. The launch represents yet another major milestone for world renowned Chinese medical software company, Shanghai based Vital Strategic Research Institute (VSRI). VSRI is a medical research firm with a long history of expertise in design, clinical trials and global research. VSRI has collaborated with pharmaceutical giants such as Pfizer and Bristol-Myers Squibb. International partners in this latest undertaking include U.S. medical giants, the University of Washington, the University of Arizona and the University of Minnesota.

Further, the Company's CEO, James Tilton, has a long and distinguished history of success in the field of cardiology and healthcare. In February 2000, a company Mr. Tilton headed, announced that it had received approval from the Food and Drug Administration (FDA) for its personal computer-based electrocardiogram monitor known as "The Tracker." Source: Medscape Medical News, February 2000.

http://www.medscape.com/index/list_964_370

VSRI has websites in both English and Chinese.

http://www.vitalstrategic.com/collaborators.html

http://www.vitalstrategic.com.cn/Home/cooperatingagency

NSAV also announced that its acquisition of VSRI's parent company, Shanghai Hua Si Tai Medical Consulting Co., Ltd., which was signed on May 8, 2017, is moving ahead smoothly and is on track to close very soon. The Company would like to inform all shareholders that the 60 day closing date stated in the acquisition agreement, was merely a target date and has no relevance on the validity of the agreement. NSAV, which expects to complete its financial statements this week, is awaiting the completion of VSRI's audited financial statements. NSAV is an SEC fully reporting company and as such, must obtain PCAOB audits according to U.S. GAAP, prior to closing any acquisition. The Company doesn't foresee any difficulty in obtaining VSRI's audited financial statements, as its December 31, 2016 and June 30, 2017 accounts have already been released to the public and currently appear on the NSAV corporate website.

James Tilton, president of NSAV, stated, "As you are all aware, cardiovascular disease is the leading global cause of death and is projected to grow by an additional 35% by 2030. There can be no debate that websites like Heart Rescue are indispensable and save lives."

NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the legal medical cannabis and hemp industries, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services, patents and trademarks and information technology.

The NSAV corporate website can be accessed at http://nsavholdinginc.com

The NSAV Twitter account can be accessed at https://twitter.com/NSAV_MJTechCo

The NSAV Facebook account can be accessed at https://www.facebook.com/NSAVHolding/

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of NSAV Holding, Inc. to accomplish its stated plan of business. NSAV Holding, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by NSAV Holding, Inc. or any other person.

For further information please contact NSAV 1 (570- 595-2432) NEXT ARTICLE

More From BioPortfolio on "NSAV Announces Launch of Heartrescue.net "

Quick Search
Advertisement
 

Relevant Topics

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...